Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 39Neoplasms 37Depression 29Prostatic Neoplasms 23Fatigue 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Multiple Myeloma 15Lymphoma, Follicular 15Lymphoma, Large B-Cell, Diffuse 13Carcinoma, Non-Small-Cell Lung 13Anxiety Disorders 13Lymphoma, Mantle-Cell 12Leukemia, Lymphocytic, Chronic, B-Cell 12Burkitt Lymphoma 12Pain 11Lymphoma, Non-Hodgkin 11Lymphoma, B-Cell, Marginal Zone 11Lung Neoplasms 11Lymphoma, Large-Cell, Immunoblastic 10Leukemia, Myeloid, Acute 10Colorectal Neoplasms 10Leukemia, Myeloid, Chronic-Phase 9Hodgkin Disease 9Blast Crisis 9Vomiting 8Nausea 8Lymphoma 8Leukemia, Myeloid, Accelerated Phase 8Head and Neck Neoplasms 8Uterine Cervical Neoplasms 7

Interventions

pembrolizumab 92Gemcitabine 55Nivolumab 49Cisplatin 38atezolizumab 31Carboplatin 30avelumab 25enfortumab vedotin 24Docetaxel 23Magnetic Resonance Spectroscopy 18Ipilimumab 17Paclitaxel 16Mitomycin 15Specimen Handling 14durvalumab 11toripalimab 10sacituzumab govitecan 10Pemetrexed 10cabozantinib 9Taxes 8vinflunine 7Cyclophosphamide 7tislelizumab 6Injections 6Bevacizumab 6pemigatinib 5fludarabine 5disitamab vedotin 5Standard of Care 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Transitional Cell × Therapeutics × Clear all
NCT03053635 2018-08-20

Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients

TheralaseĀ® Technologies Inc.

Phase 1 Completed
6 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚔